



Docket No. 2026-4124

PATENT

#12
B. Denny
8/22/96

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kawakami et al. Group Art Unit: 1806
Serial No. : 08/231,565 Examiner: S. Huff
Filed : April 22, 1994
For : MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC
AND THERAPEUTIC METHODS

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement of July 3, 1996, Applicants elect the subject matter of claims 1-5 drawn as the nucleic acid sequence of MART-1, classified in Class 536, subclass 23.1+. Applicants, however, traverse this Restriction Requirement for the reasons discussed below. Applicants were given until August 2, 1996 to respond to the Restriction Requirement. Hence this response is timely filed.

REMARKS

The present invention relates to nucleic acid and proteins and immunogenic peptides encoding melanoma antigens. The invention also relates to therapeutic and diagnostic uses of said nucleic acid sequences, proteins and peptides. Claims 1-5 are drawn to nucleic acid sequence encoding MART-1, classified in Class 536, Subclass 23.1+